statin and fitness provide additive mortality benefit

No big shocker.  Turns out the statins and increased exercise fitness are synergistic in mortality benefit in study of veterans (see cad statin and fitness additive lancet 2013 in dropbox).  In brief:
 
--10K people, median age 59, who had ETT between 1986-2011 (these results were used to determine their fitness, based on peak MET achieved) and reviewed for use of statins, followed ave of 10 years. This was just number-crunching analysis (people may have gotten their lipids checked routinely or to assess ischemia sx and happened to have an exercise test for whatever reason)
 
--primary outcome all-cause mortality
--ave chol pretreatment was the same (232) as well as HDL (46) and LDL (154), though chol decreased in those on statins (170 vs 197) and LDL (100 vs 139) without change in HDL
--mortality rate was 18.5% in those on statins vs 27.7% on those not.
--in those on statins: those most fit had 70% lower mortality than those least fit.
--in those not on statins: those most fit (as compared to those least fit on statins as the reference) there was a 47% decreased mortality and in those most fit a 35% increased mortality
--both fitness and statins clearly affected mortality highly significantly, with clear benefit of statins in each fitness category; however, the most fit group (>9.0 METs) not on statins had about the same mortality as the moderate to fit range (5.1-9 METs) on statins (lots of numbers in the article, but for your reference, mortality % for least fit/no statin=52% dec to 37% with statin; moderately fit with not statin 34% vs 21% with statin; fit with no statins 20% vs 10% with statin, highly fit with no statin 13% vs 6% with statin.
 
 
Note that this is an observational study (ie not an intervention study where statin +/- exercise given and check on outcome).  Since a reasonable percentage of fitness is genetic and not related to actually working out in the gym, hard to make firm conclusions.  But, it does reinforce that we should (probably) be discussing lifestyle issues pretty aggressively even in those on statins (ie, not just perscribe statin for cardioprotection/mortality benefit and leave it at that).

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more